Jasper Therapeutics Inc.-CW26JSPRWPreferred / convertible
13F holders, Q1 2025 (March 31)5holders
0new positions
0sold out
$0.14avg. 13F price*
At the end of Q1 2025, 5 institutions reported holding Jasper Therapeutics Inc.-CW26 (JSPRW) in their 13F filings, unchanged from Q4 2024. 0 opened new positions and 0 sold out. The largest holders were Walleye Capital LLC ($80K), TENOR CAPITAL MANAGEMENT Co., L.P. ($36K) and Zazove Associates LLC ($8K).
- Company
- Jasper Therapeutics Inc.-CW26
- CUSIP
- 471871111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 15,843 shares sold, net −15,843 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Walleye Capital LLC | — | Reduce -2.4% | 560,061 | $80K |
| TENOR CAPITAL MANAGEMENT Co., L.P. | — | No change | 250,000 | $36K |
| Zazove Associates LLC | — | No change | 65,456 | $8K |
| Walleye Trading LLC | — | Reduce -2.8% | 34,142 | $5K |
| UBS Group AG | — | Reduce -49.3% | 1,304 | $133 |
"% of holder's portfolio" is JSPRW's weight in each manager's 13F, not the share of Jasper Therapeutics Inc.-CW26 the manager owns.